Close

Anti-C12H18N4O7 T cell receptor (MAV36), pCDTCR1 (TCR-YC0175)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The TRAV1-2-TCRs (MAV14, MAV21, and MAV36) all bound MR1 tetramer in an Ag-dependent manner and, similar to the TRAV1-2+ TCRs, variable Ag recognition was observed. For example, MAV36 was clearly dependent on the presence of 5-OP-RU but not 6-FP or Ac-6-FP, whereas MAV14 bound to MR1 tetramers loaded with 5-OP-RU, 6-FP, and Ac-6-FP, albeit to varying degrees. The MAV21 weakly bound to human MR1-5-OP-RU tetramer and did not bind mouse MR1-5-OP-RU tetramer. However, MAV21 bound human MR1 6-FP and Ac-6-FP tetramers with high intensity, highlighting that this TRAV1-2- TCR selectively detects folate-derivative ligands.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • C12H18N4O7
  • Epitope
  • 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil
  • Format
  • Non-Modified TCR
  • Allele
  • human MR1
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
  • TCR Clone
  • MAV36
  • Host Species
  • Human

Target

  • Introduction
  • An aminouracil that is D-ribitol in which the hydroxy group at position 1 is substituted by the 6-amino group of 6-amino-5-(2-oxopropylideneamino)uracil. Unstable mucosal-associated invariant T (MAIT)-activating antigen, formed by non-enzymatic reaction between 5-amino-6-D-ribitylaminouracil and methylglyoxal.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Human anti-C12H18N4O7 T cell receptor (MAV36), pCDTCR1 (TCR-YC0175). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.